ENTRY       D12271                      Drug
NAME        Batiraxcept (USAN)
FORMULA     C4166H6450N1130O1290S26
EXACT_MASS  93780.6588
MOL_WEIGHT  93838.2762
SEQUENCE    EESPFVSNPG NITGARGLTG TLRCQLQVQG EPPEVHWLRD GQILELVDST QTQVPLGEDE
            QGDWIVASQL RITSLQLSDT GQYQCLVFLG HQTFVSQPGY VRLEGLPYFL EEPEDRTVAA
            NTPFNLSCQA QGPPEPVDLL WLQDAVPLAT APGHGPQRSL HVPGLNKTSS FSCEAHNAKG
            VTTSRTATIT VLPQQGGGGS DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT
            CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK
            CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE
            WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS
            LSLSPG
            (Disulfide bridge: 24-85, 128-173, 206-206', 209-209', 241-301, 341-405, 24'-85', 128'-173', 241'-301', 347'-405)
  TYPE      Peptide
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
COMMENT     Treatment of ovarian cancer
TARGET      AXL [HSA:558] [KO:K05115]
BRITE       Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               AXL family
                AXL
                 D12271  Batiraxcept (USAN)
DBLINKS     CAS: 2268717-61-7
///
